Care Access Acquires Brazil Research Site to Expand Decentralized Clinical Trial Capabilities to Latin America

This marks the company’s first major step in expanding its unique clinical trial delivery model across the globe BOSTON–(BUSINESS WIRE)–Care Access, the world leader in decentralized clinical trials delivery, today announced the acquisition of Instituto Brasil de Pesquisa Clínica (IBPClin), a clinical trial center in Rio de Janeiro, Brazil, as the first step to bring … [Read more…]

Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace

Article highlights promising preliminary results and path forward for FDA-approved stem cell treatment study NEW YORK–(BUSINESS WIRE)–The Tisch Multiple Sclerosis Research Center of New York, the world’s largest independent research center focusing on MS, is proud to announce that its FDA-approved stem cell treatment study was featured in an article in BioSpace. Preliminary analysis of … [Read more…]

Four-Year Results Show Aerin Medical’s VivAer® Treatment Provides Significant, Sustained Relief of Nasal Obstruction Symptoms

Long term follow-up published in International Forum of Allergy & Rhinology demonstrates treatment durability for nasal valve collapse SUNNYVALE, Calif.–(BUSINESS WIRE)–#VivAer—Aerin Medical Inc., a company that provides Ear, Nose and Throat (ENT) physicians with non-invasive solutions to treat chronic nasal conditions, today announced that the International Forum of Allergy & Rhinology published positive four-year results … [Read more…]

Top 10 Warning Signs of Memory Loss & How to Seek Help According to Beverly Sanborn, Belmont Village Senior Living

HOUSTON–(BUSINESS WIRE)–As older adults continue to age, it can be difficult for both them and their loved ones to distinguish between the signs and symptoms associated with ‘normal’ aging, such as stress and cognitive decline, and a common precursor to dementia called Mild Cognitive Impairment (MCI) – especially when it’s in its very early stages. … [Read more…]

Chemed Corporation Announces a Five-Year $550 Million Amended and Restated Senior Secured Credit Facility

CINCINNATI–(BUSINESS WIRE)–Chemed Corporation (“Chemed”) (NYSE:CHE) announced that it has entered into $550 million of amended and restated senior secured credit facilities (“Credit Facilities”). JPMorgan Chase Bank, N.A. acted as the Administrative Agent, and Lead-left Bookrunner and Joint Lead Arranger. Bank of America, N.A. acted as Co-Syndication Agent and Joint Bookrunner/Lead Arranger. PNC Bank National Association … [Read more…]

GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community

Inaugural grant awarded to the HealthTree Foundation, a pioneering non-profit organization whose proposal will address disparities in care in multiple myeloma PHILADELPHIA–(BUSINESS WIRE)–#Diversity–GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit organization helping patients learn more about … [Read more…]

TAE Life Sciences Showcases Targeted Drugs to Support Novel BNCT Accelerator System at 60th PTCOG Conference

FOOTHILL RANCH, Calif.–(BUSINESS WIRE)–TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today presented in vivo and in vitro boron delivery data using the company’s novel compounds at the 60th Particle Therapy Co-Operative Group (PTCOG) Conference, occurring June 27 – July 2, 2022. “The identification of these targeted … [Read more…]

Receptor Life Sciences Announces First Patient Dosed with RLS103 (Inhaled Dry Powder CBD) in Phase 1b/2a Clinical Study in Acute Anxiety within Social Anxiety Disorder

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a clinical-stage pharmaceutical company developing innovative therapies to address central nervous system disorders, announced that the first patient has been dosed in its Phase 1b/2a clinical safety, tolerability, and efficacy study evaluating RLS103 in adult patients with acute anxiety within social anxiety disorder (SAD). RLS103, a dry powder inhaled cannabidiol … [Read more…]

IACTA Pharmaceuticals Announces Expansion of Scientific Advisory Board with Two World-Renowned Key Opinion Leaders

GUAYNABO, Puerto Rico–(BUSINESS WIRE)–IACTA Pharmaceuticals, Inc. (“IACTA”), an innovation leader in ophthalmic therapeutics, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Dr. Richard L. Abbott and Dr. Lixin Xie. Dr. Abbott and Professor Xie join an established group of global advisors who will provide strategic insight and guidance to … [Read more…]

Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile

— STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents — — Approximately 3,400 patients per year diagnosed with NSCLC tumors that express EGFR with Exon 20 insertion mutations in the United States — — Preclinical data to … [Read more…]